Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.56 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.56 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.56 |
| ▸ | CETP | P11597 | 1/20 | 0.50 |
| ▸ | GJB2 | P29033 | 1/20 | 0.48 |
| ▸ | IGF2R | P11717 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14691537 | 1.00 | MAPK1 (0.64) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL16678936 | 1.00 | MAPK1 (0.64) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL16678934 | 1.00 | MAPK1 (0.64) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL14691296 | 1.00 | MAPK1 (0.64) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL503177 | 1.00 | MAPK1 (0.64) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL606489 | 0.98 | MAPK1 (0.67) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL17547754 | 0.98 | MAPK1 (0.63) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL605059 | 0.98 | MAPK1 (0.67) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL14673519 | 0.98 | MAPK1 (0.63) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL2448497 | 0.98 | MAPK1 (0.63) | MAPK1LGALS8LGALS3LGALS4CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3369738-B1 | METHOD FOR MAKING NICOTINOYL RIBOSIDES AND NICOTINAMIDE BETA-RIBOSIDE | CORNELL RES FOUNDATION INC (US) | 2020-05-20 | — | — | EP | claimed |
| EP-3369738-A1 | NICOTINYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | Cornell Research Foundation, Inc. (US) | 2018-09-05 | — | — | EP | claimed |
| EP-1957086-B1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL RES FOUNDATION INC (US) | 2018-05-02 | — | — | EP | claimed |
| US-20120172584-A1 | NICOTYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL UNIVERSITY (US) | 2012-07-05 | — | — | US | claimed |
| US-8106184-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2012-01-31 | — | — | US | claimed |
| EP-1957086-A2 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-08-20 | — | — | EP | claimed |
| WO-2007061798-A2 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070117765-A1 | Nicotinoyl riboside compositions and methods of use | CORNELL RESEARCH FOUNDATION INC. | 2007-05-24 | — | — | US | claimed |
| US-11633414-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2023-04-25 | — | — | US | disclosed |
| US-20210353657-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL UNIVERSITY (US) | 2021-11-18 | — | — | US | disclosed |
| US-11077129-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3730507-A1 | NICOTINOYL RIBOSIDE AND NICOTINAMIDE RIBOSIDE COMPOSITIONS FOR USE IN REDUCING TOXICITY INDUCED BY HMG-COA REDUCTASE INHIBITORS | Cornell Research Foundation, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200289535-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL UNIVERSITY | 2020-09-17 | — | — | US | disclosed |
| US-10668096-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2020-06-02 | — | — | US | disclosed |
| CN-101701027-A | Catalytic cracking method of nucleoside compound | UNIV ZHEJIANG TECHNOLOGY | 2010-05-05 | — | — | CN | disclosed |
| US-20100036112-A1 | Process for Making 5-Azacytosine Nucleosides and Their Derivatives | SCINOPHARM TAIWAN LTD. | 2010-02-11 | — | — | US | disclosed |
| WO-2010017547-A1 | PROCESS FOR MAKING 5-AZACYTOSINE NUCLEOSIDES AND THEIR DERIVATIVES | SCINOPHARM TAIWAN LDT. (TW) | 2010-02-11 | — | — | WO | disclosed |
| EP-1957086-A2 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007061798-A2 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070117765-A1 | Nicotinoyl riboside compositions and methods of use | CORNELL RESEARCH FOUNDATION INC. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172584-A1 | NICOTYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | NNT, NAMPT, NAPRT | MAPK1 3861/4885LGALS8 1465/4885LGALS3 1515/4885 |
| US-20100036112-A1 | Process for Making 5-Azacytosine Nucleosides and Their Derivatives | DCTD, DUT, DPYD | MAPK1 3137/4885LGALS8 1977/4885LGALS3 2641/4885 |
| US-11077129-B2 | Nicotinoyl riboside compositions and methods of use | NNT, CD38, NAMPT | MAPK1 3872/4885LGALS8 1202/4885LGALS3 1237/4885 |
| US-20070117765-A1 | Nicotinoyl riboside compositions and methods of use | NNT, CD38, NAMPT | MAPK1 3872/4885LGALS8 1202/4885LGALS3 1237/4885 |
| US-20200289535-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | NNT, CD38, NAMPT | MAPK1 3872/4885LGALS8 1202/4885LGALS3 1237/4885 |
| US-10668096-B2 | Nicotinoyl riboside compositions and methods of use | NNT, CD38, NAMPT | MAPK1 3872/4885LGALS8 1202/4885LGALS3 1237/4885 |
| US-20210353657-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | NNT, CD38, NAMPT | MAPK1 3872/4885LGALS8 1202/4885LGALS3 1237/4885 |
| US-11633414-B2 | Nicotinoyl riboside compositions and methods of use | NNT, CD38, NAMPT | MAPK1 3872/4885LGALS8 1202/4885LGALS3 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.